382 related articles for article (PubMed ID: 30029679)
1. Acid ceramidase deficiency: Farber disease and SMA-PME.
Yu FPS; Amintas S; Levade T; Medin JA
Orphanet J Rare Dis; 2018 Jul; 13(1):121. PubMed ID: 30029679
[TBL] [Abstract][Full Text] [Related]
2. Spinal muscular atrophy-like phenotype in a mouse model of acid ceramidase deficiency.
Nagree MS; Rybova J; Kleynerman A; Ahrenhoerster CJ; Saville JT; Xu T; Bachochin M; McKillop WM; Lawlor MW; Pshezhetsky AV; Isaeva O; Budde MD; Fuller M; Medin JA
Commun Biol; 2023 May; 6(1):560. PubMed ID: 37231125
[TBL] [Abstract][Full Text] [Related]
3. Acid Ceramidase Deficiency: Bridging Gaps between Clinical Presentation, Mouse Models, and Future Therapeutic Interventions.
Kleynerman A; Rybova J; Faber ML; McKillop WM; Levade T; Medin JA
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830643
[TBL] [Abstract][Full Text] [Related]
4. Acid ceramidase deficiency associated with spinal muscular atrophy with progressive myoclonic epilepsy.
Gan JJ; Garcia V; Tian J; Tagliati M; Parisi JE; Chung JM; Lewis R; Baloh R; Levade T; Pierson TM
Neuromuscul Disord; 2015 Dec; 25(12):959-63. PubMed ID: 26526000
[TBL] [Abstract][Full Text] [Related]
5. ASAH1 pathogenic variants associated with acid ceramidase deficiency: Farber disease and spinal muscular atrophy with progressive myoclonic epilepsy.
Elsea SH; Solyom A; Martin K; Harmatz P; Mitchell J; Lampe C; Grant C; Selim L; Mungan NO; Guelbert N; Magnusson B; Sundberg E; Puri R; Kapoor S; Arslan N; DiRocco M; Zaki M; Ozen S; Mahmoud IG; Ehlert K; Hahn A; Gokcay G; Torcoletti M; Ferreira CR
Hum Mutat; 2020 Sep; 41(9):1469-1487. PubMed ID: 32449975
[TBL] [Abstract][Full Text] [Related]
6. Spinal muscular atrophy associated with progressive myoclonus epilepsy.
Topaloglu H; Melki J
Epileptic Disord; 2016 Sep; 18(S2):128-134. PubMed ID: 27647482
[TBL] [Abstract][Full Text] [Related]
7. Spinal muscular atrophy and Farber disease due to ASAH1 variants: A case report.
Lee BH; Mongiovi P; Levade T; Marston B; Mountain J; Ciafaloni E
Am J Med Genet A; 2020 Oct; 182(10):2369-2371. PubMed ID: 32627310
[TBL] [Abstract][Full Text] [Related]
8. ASAH1-related disorders: Description of 15 novel pediatric patients and expansion of the clinical phenotype.
Mahmoud IG; Elmonem MA; Zaki MS; Ramadan A; Al-Menabawy NM; El-Gamal A; Mansour L; Issa MY; Abdel-Hamid MS; Abdel-Hady S; Khalifa I; Ibrahim A; Solyom A; Rolfs A; Selim L
Clin Genet; 2020 Dec; 98(6):598-605. PubMed ID: 32875576
[TBL] [Abstract][Full Text] [Related]
9. Spinal muscular atrophy with progressive myoclonic epilepsy linked to mutations in ASAH1.
Yildiz EP; Yesil G; Bektas G; Caliskan M; Tatlı B; Aydinli N; Ozmen M
Clin Neurol Neurosurg; 2018 Jan; 164():47-49. PubMed ID: 29169047
[TBL] [Abstract][Full Text] [Related]
10. Acid Ceramidase Depletion Impairs Neuronal Survival and Induces Morphological Defects in Neurites Associated with Altered Gene Transcription and Sphingolipid Content.
Kyriakou K; Lederer CW; Kleanthous M; Drousiotou A; Malekkou A
Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32111095
[TBL] [Abstract][Full Text] [Related]
11. Hepatic pathology and altered gene transcription in a murine model of acid ceramidase deficiency.
Yu FPS; Molino S; Sikora J; Rasmussen S; Rybova J; Tate E; Geurts AM; Turner PV; Mckillop WM; Medin JA
Lab Invest; 2019 Oct; 99(10):1572-1592. PubMed ID: 31186526
[TBL] [Abstract][Full Text] [Related]
12. Acid Ceramidase Deficiency in Mice Leads to Severe Ocular Pathology and Visual Impairment.
Yu FPS; Sajdak BS; Sikora J; Salmon AE; Nagree MS; Gurka J; Kassem IS; Lipinski DM; Carroll J; Medin JA
Am J Pathol; 2019 Feb; 189(2):320-338. PubMed ID: 30472209
[TBL] [Abstract][Full Text] [Related]
13. Systemic ceramide accumulation leads to severe and varied pathological consequences.
Alayoubi AM; Wang JC; Au BC; Carpentier S; Garcia V; Dworski S; El-Ghamrasni S; Kirouac KN; Exertier MJ; Xiong ZJ; Privé GG; Simonaro CM; Casas J; Fabrias G; Schuchman EH; Turner PV; Hakem R; Levade T; Medin JA
EMBO Mol Med; 2013 Jun; 5(6):827-42. PubMed ID: 23681708
[TBL] [Abstract][Full Text] [Related]
14. Clinical features and genetics in non-5q spinal muscular atrophy caused by acid ceramidase deficiency.
Axente M; Shelby ES; Mirea A; Sporea C; Badina M; Padure L; Ion DA
J Med Life; 2021; 14(3):424-428. PubMed ID: 34377212
[TBL] [Abstract][Full Text] [Related]
15. rAAV-mediated over-expression of acid ceramidase prevents retinopathy in a mouse model of Farber lipogranulomatosis.
Zhang H; Nagree MS; Liu H; Pan X; Medin JA; Lipinski DM
Gene Ther; 2023 Apr; 30(3-4):297-308. PubMed ID: 35902747
[TBL] [Abstract][Full Text] [Related]
16. Acid ceramidase and the treatment of ceramide diseases: The expanding role of enzyme replacement therapy.
Schuchman EH
Biochim Biophys Acta; 2016 Sep; 1862(9):1459-71. PubMed ID: 27155573
[TBL] [Abstract][Full Text] [Related]
17. Five patients with spinal muscular atrophy-progressive myoclonic epilepsy (SMA-PME): a novel pathogenic variant, treatment and review of the literature.
Karimzadeh P; Najmabadi H; Lochmuller H; Babaee M; Dehdahsi S; Miryounesi M; Amirsalari S; Rayegani SM; Tonekaboni SH
Neuromuscul Disord; 2022 Oct; 32(10):806-810. PubMed ID: 36309462
[TBL] [Abstract][Full Text] [Related]
18. A simple fluorogenic method for determination of acid ceramidase activity and diagnosis of Farber disease.
Bedia C; Camacho L; Abad JL; Fabriàs G; Levade T
J Lipid Res; 2010 Dec; 51(12):3542-7. PubMed ID: 20871013
[TBL] [Abstract][Full Text] [Related]
19. Structural basis for the activation of acid ceramidase.
Gebai A; Gorelik A; Li Z; Illes K; Nagar B
Nat Commun; 2018 Apr; 9(1):1621. PubMed ID: 29692406
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
